Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.48 |
| ▸ | FEN1 | P39748 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17367677 | 0.82 | KDM4E (0.62) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL15915443 | 0.82 | ALDH1A1 (0.62) | ALDH1A1LMNAKDM4EHTTALOX5AP | |
| SCHEMBL3087652 | 0.76 | POLB (0.59) | TSHRMAPTL3MBTL1ALDH1A1LMNA | |
| SCHEMBL15917017 | 0.76 | EPHX2 (0.52) | TSHRALDH1A1LMNAKDM4EHTT | |
| SCHEMBL29973515 | 0.74 | TSHR (0.66) | TSHRMAPTALDH1A1KMT2AKDM4E | |
| SCHEMBL15917236 | 0.74 | TSHR (0.71) | TSHRMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL15914906 | 0.73 | ALDH1A1 (0.52) | TSHRALDH1A1LMNAKMT2AKDM4E | |
| SCHEMBL15916530 | 0.73 | TSHR (0.75) | TSHRMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL15916754 | 0.73 | TSHR (0.75) | TSHRMAPTL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL2960619 | 0.72 | MEN1 (0.62) | GAAMAPTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495359-A1 | FLAP MODULATORS | Janssen Pharmaceutica NV (BE) | 2019-06-12 | — | — | EP | disclosed |
| EP-3070085-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2951170-B1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-24 | — | — | EP | disclosed |
| US-9884878-B2 | FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-02-06 | — | — | US | disclosed |
| US-9745328-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-29 | — | — | US | disclosed |
| EP-3070085-A1 | FLAP MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2016-09-21 | — | — | EP | disclosed |
| US-20150376212-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-31 | — | — | US | disclosed |
| US-20150259357-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-17 | — | — | US | disclosed |
| US-9079866-B2 | Flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| US-20140221311-A1 | FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376212-A1 | FLAP MODULATORS | FEN1, PGF, TBXA2R | GAA 3237/4885TSHR 2884/4885MAPT 4864/4885 |
| US-20150259357-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | GAA 2916/4885TSHR 2461/4885MAPT 4867/4885 |
| US-20140221311-A1 | FLAP MODULATORS | PGF, FEN1, TBXA2R | GAA 2916/4885TSHR 2461/4885MAPT 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.